Veterinary Anti-infectives Market Size was valued at USD 1.32 billion in 2021, growing at a CAGR of 3.6% from 2022-28. Anti-infectives are substances that have the ability to counter the malfunction caused by foreign bacteria, fungi, virus, parasites, and among others. Anti-infectives are used to prevent or completely cure various infectious diseases. These substances prevent the chances of contracting the infection by making the body immune from the specific bacterial infection. Commonly occurred veterinary infectious diseases include zoonotic diseases and foodborne disorders. Veterinary Anti-infectives Market report gives a comprehensive outlook across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). This report gives historical, current, and future market sizes (US$ Mn) of drug type, disease type, species type, route of administration and end user and geographic regions. This report studies market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the market report includes regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed the market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the market report include suppliers, manufacturers, marketers, policymakers. Key Developments: In March 2016, Dechra Pharmaceuticals acquired Putney Inc. for expanding the veterinary products portfolio and development of pipeline products including veterinary anti-infectives. In May 2013, Novabay Pharmaceuticals inked a collaboration agreement with Virbac for exploring uses of veterinary anti-infective drug auriclosene.